Brefeldin A

Catalog No.S7046

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.

Size Price Stock Quantity  
In DMSO USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Immunofluorescence staining of LC3 protein expression of U2OS cells treated with DMSO (negative control), Rap (positive control, 500 nM), Tha (1 μM), Tun (2 μg/mL), BFA (10 μg/mL), and DTT (4 mM) for 8 h. Immunoblot of ER-phagy-related proteins of U2OS cells treated with four ER stress inducers.

    Nanoscale, 2018, 10(18):8796-8805. Brefeldin A purchased from Selleck.

    Cells were treated with brefeldin A or manumycin A, and the resulting supernatant was collected after 48 h for exosomal preparation (lanes 1 and 2), or exosomes obtained from C81 cells were trypsin-treated or freeze/thawed (F/T) and then trypsin-treated (lanes 3 and 4). Lanes 5 and 6, input exosome controls from C81 or CEM cells, respectively. Resulting exosomes were assayed for the presence of Tax by Western blotting.

    J Biol Chem, 2014, 289(32):22284-305.. Brefeldin A purchased from Selleck.

  • CSFV proliferation in ST cells with or without BFA was observed by IFA at 24, 48 and 72 hpi.

    J Biosci, 2018, 42(1):43-56. Brefeldin A purchased from Selleck.

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5] Brefeldin A could improve the HDR(homology-directed repair) efficiency. It is an enhancer of CRISPR-mediated HDR[6].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 M3zqdWZ2dmO2aX;uJGF{e2G7 M1XGUVIh|ryP M{[2RVEhcA>? NXG3dYxncW6qaXLpeJMhfGinIFytSG9RSSBqMkFCpO69VSlvaX7keYNm\CC2cnHud4lmdnRiRWLLNU8zKHCqb4PwbI9zgWyjdHnvcuKh NVLveXpnOjZ|NkOxPVE>
C2C12 M1zPRWZ2dmO2aX;uJGF{e2G7 M3O2bFHDqM7:Zz;tcC=> M122cFHDqGh? MkG4ZYJwdGm|aHXzJIN6fG:taX7lJJJmdGWjc3Wg[pJwdSCFMlOxNkBugW:2dXLldy=> M4TsZ|I3OjlzMke5
MEFs WT MoLJSpVv[3Srb36gRZN{[Xl? MVy1xsDPxE1? Mo\nNlAhdWmw MYrjZZV{\XNicnXzbYRmdnRiZX76fY1meyC|dXPoJIF{KE6DR2StS2ZRNCC2bzDkbYZnfXOnIHLhZ4shfG9idHjlJGVT M2rP[VI3OTl4MEKz
MEFs VAMP7 KO NVLXWYwxTnWwY4Tpc44hSXO|YYm= M3\LWlXDqM7:TR?= MWOyNEBucW5? MomwZ4F2e2W|IILld4ll\W62IHXufplu\XNic4XjbEBieyCQQVfUMWdHWCxidH:g[Iln\nW|ZTDiZYNsKHSxIITo[UBGWg>? MXmyOlE6PjB{Mx?=
SMCs NUn5XYl3TnWwY4Tpc44hSXO|YYm= NXy4XnFCOTEEoNM1[{9udA>? NFTqU4UxNTF{IHi= MYHEUXNQ NWLGSXNIe2ixd4OgZUB1emWwZDD0c5diemS|IHGgbIlocGW{IHPvcoNmdnS{YYTpc44hd2ZidHjlJGVTN1OUIH7leJdwemtiaX6geIhmKHCncnnueYNt\WG{IHHy[YHDqA>? NFOwbYQzPjF5MkC4NC=>
SMCs M3H3OGZ2dmO2aX;uJGF{e2G7 MnXyNVDDqML3Zz;tcC=> NV;mfmVLOC1zMjDo MofjSG1UVw>? NGPCUVJk[XW|ZYOgZUB1emGwc3nlcpQhS2F{K9MgdoVt\WG|ZTDmdo9uKHSqZTDFVk9UWsLi MVyyOlE4OjB6MB?=
HEMC-1 NE\aVHlHfW6ldHnvckBCe3OjeR?= MUGwMlHDqML3Zz;tcC=> MWGyOOKhcA>? NX[0XYYy[2G3c3XzJIEhcGmpaHXyJIlvcGmkaYTvdpkh\W[oZXP0JI9vKGW6b3P5eI9{cXNidHjhckBvd2OxZHH6c4xm NYLaWJR{OjV7N{K3OVk>
HUVEC MX3GeY5kfGmxbjDBd5NigQ>? NFrmVYYyOMLizszN MkHDNeKhcA>? MU\EUXNQ NIL4cYFi[m:uaYPo[ZMhcHmyb4jpZU1qdmS3Y3XkJJJmdGWjc3Wgc4YhSVSSIH\yc40h[XCrY3HsJIFv\CCkYYPvcIF1\XKjbDDzeZJn[WOncx?= MVeyOVk2Pjl6OB?=
HUVEC NEToUIlHfW6ldHnvckBCe3OjeR?= M1rCN|ExyqEQvF2= MXqxxsBp MkLzSG1UVw>? M33lUYlv[3KnYYPld:KhfGinIH71cYJmeiCjbnSgbY51\W6|aYT5JI9nKG[udX;y[ZNk\W62IHHy[YF{KGW|cHXjbYFtdHliaX6gdIVzcW63Y3zlZZIhe3CjY3W= M3XjUVI2QTV4OUi4
Caco-2 MniwSpVv[3Srb36gRZN{[Xl? NXfy[IdVOi53IN88US=> MoewN|AhdWmw NVnXcnc5[XS2ZX71ZZRmeyC2aHWgWGdHNc7{MT3t[YRq[XSnZDDpcoNz\WG|ZTDpckBUTVKWIH\1coN1cW:w MWeyOVk2PDl|MR?=
NRK M176OmZ2dmO2aX;uJGF{e2G7 NYG4THJEOjBy4pEFcocwdWx? NWG3fZI3POLChXi= M2i0[2ROW09? NILhPGRz\XOldXXzJI1qfG:2aXOgdJJw\3Knc4Ppc44> MkCwNlU6PDh3OE[=
HeLa NGDMbGxHfW6ldHnvckBCe3OjeR?= M2OwXFIxOOLChX7nM41t NGO5ZoM{KGh? MUnEUXNQ MWnpcoR2[2W|IITo[UBienSrZnnjbYFtKGK{ZXHrMZVxKG:oIITo[UBId2ypaTDjc41xdGW6 MWWyOVk1QDV6Nh?=
COS MX3GeY5kfGmxbjDBd5NigQ>? M2LJ[lEh|rypL33s MV:zJIg> M4e5RYNwdXCuZYTlcJkh\Gm|cHXyd4V{KHSqZTDBVE0yKHOrZ37hcOKh MX:yOVkyPTlyMB?=
DF1  MoGxSpVv[3Srb36gRZN{[Xl? NV;hT3ZUOcLizszNxsA> MVe0PEBp MmTqSG1UVw>? M4H1cYRqe3CncoPld:KhfGinIHX4c4dmdm:3czDDV2didE6DY2SyJJBzd3SnaX6= MX[yOVgxPzB3NB?=
nHDFs  NUDCXWtQTnWwY4Tpc44hSXO|YYm= Mn7lNeKh|ryPwrC= Ml;qNuKhcA>? MVXwdoV3\W62czD0bIUh[XO|ZX3icJkhd2ZiY4n0c5NwdGmlIHPvZZQheHKxdHXpcpMhd262bzDHc4xocSCvZX3idoFv\XN? MWGyOVc4OjZzNh?=
FRT  MX\GeY5kfGmxbjDBd5NigQ>? MUW1JO69\y:vbB?= M2TvbVLDqGh? MoPCZoxw[2u|IITyZYZncWOtaX7nJJRpem:3Z3igeIhmKEexbHfpJINwdXCuZYigZpkhcW6qaXLpeIlv\yCHUj30c{1Id2ypaTD0doFve3CxcoS= MVeyOVc3PzFzNR?=
FRT  NIf5XXZHfW6ldHnvckBCe3OjeR?= MV:1JO69\y:vbB?= Mne4NuKhcA>? MUfwdoV3\W62czD0bIUhcW6lcnXhd4UhcW5iY3zlZZZm\CEQsTDzeYJ2dmm2czD3bIVvKFuQYTvdbeKhf2G|IILl[JVk\WR? M37ZfVI2PzZ5MUG1
HepG2  MYrGeY5kfGmxbjDBd5NigQ>? NUC4SWxyOeLCidM1UeKh NEfHfFUzPCCq NFv5XGRFVVOR MUnk[YNz\WG|ZYOgeIhmKGyndnXsJI9nKFC[UjDtVm5C MkmwNlU3OTZ3OUe=
SMCs M1zwZ2Z2dmO2aX;uJGF{e2G7 MkLJNe69\y:vTB?= M{LqXFMhcA>? NEW4bpBi[2O3bYXsZZRmeyCFTmDZNkBxem:2ZXnuJIlvKHSqZTDFVkBkd22yYYL0cYVvfCCjbnSgco8hdG:wZ3XyJINwNWyxY3HsbZpm\CC5aYToJJRp\SCJb3znbUBu[XKtZYNCpC=> M1XBUVI2PTh7NEK1
OB-6 MnfSRZBweHSxc3nzJGF{e2G7 NXWxbpFHOi55wrFOwG0> NUjvSHR5PDhiaB?= M4LCXYlv\HWlZYOgZZBweHSxc3nz MnzRNlU2OzJ2OEC=
iPSC-CMs  M3[3bGZ2dmO2aX;uJGF{e2G7 MUW1NFAhdmdxbXy= NEPzOIU1QCCq NUCwT4ZZcW6lcnXhd4V{KHSqZTDpcpRmdnOrdImgc4YhfGinIHjp[4hmeiCvb3LpcIl1gSCOQV3Qd{BifCC2aHWgZ49{fCCxZjD0bIUhdG:5ZYKgcY9jcWyrdImgd5Bm[2mncx?= MVqyOVQ5QDZ4Nh?=
SP-Nluc MWXGeY5kfGmxbjDBd5NigQ>? NYKwZ5BIPSCvZz;tUC=> Mlj5OkBp MUXEUXNQyqB? NYfTcmhE[2G3c3XzJIFvKGmwY4LlZZNmKGmwIILldI9zfGW{IHHjeIl3cXS7IHnuJJRp\SCyYYLhd4l1\Q>? M4[yTFI2Ozl{OUm4
PEXEL-Nluc NIL5R4JHfW6ldHnvckBCe3OjeR?= NVvYdFAzPSCvZz;tUC=> MVO2JIg> M13mbmROW00EoB?= MmPvZ4F2e2W|IHHuJIlv[3KnYYPlJIlvKHKncH;yeIVzKGGldHn2bZR6KGmwIITo[UBx[XKjc3n0[S=> NVrpR2t2OjV|OUK5PVg>
H1299 M1[5VmZ2dmO2aX;uJGF{e2G7 NGjDPJEyOCEQvHevcYw> M1XSTVI1KGh? MYnpcoR2[2W|IHH1eI9xcGGpedMg NIO5eVYzPTN6OEm3NC=>
MDA-MB-231 MlTWR4VtdCCYaXHibYxqfHliQYPzZZk> Mlq0NQKBmzVyIN88[{9uVA>? MVq0PEBp NIrweHJGSzVywrC9JFAvODF4INM1[{9uVA>? MlG3NlU{PTZ3Nke=
MDA-MB-231 NXT0eWJGSXCxcITvd4l{KEG|c3H5 NXq3XmxyOC5zIN88[{9uVA>? M3;kVlQhcA>? NIP6fW5qdmS3Y3XzJIFxd3C2b4Ppdy=> NITvd4ozPTN3NkW2Oy=>
MDA-MB-231 MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkexNE4xOS9yLkC1JO69\y:vTB?= MkfYNlQhcA>? NFLDUmFqdmO{ZXHz[ZMhfGinIH\yZYN1cW:wIH;mJJN2[i2JMTDj[YxtKGSnYoLpdy=> MmTYNlU{PTZ3Nke=
MDA-MB-231 MlPURZBweHSxc3nzJGF{e2G7 MmjNNE4xPeLCk{Gg{txoN22O NWXPTG1MOjRiaB?= MUDpcoR2[2W|IGDBVnAhMHCxbImgRWRRNXKrYn;z[UBxd2y7bXXyZZNmNTFrIHPs[YF3[Wen M{TwXlI2OzV4NU[3
MDA-MB-231 MlvTSpVv[3Srb36gRZN{[Xl? MVmw5qCUPTBizsznM41N NF7OUIQzPCCq MWTpcohq[mm2czD0bIUh\m:{bXH0bY9vKG:oIEPEJIFv\CB{RDDjc4xwdmmncx?= MXeyOVM2PjV4Nx?=
A172 NEnQbYhHfW6ldHnvckBCe3OjeR?= Mmi1NVDDqM7:Zz;tcC=> MoDLOOKhcA>? MoDWSG1UV8Li NF7VeoFz\XO3bITzJIlvKHSqZTDy[ZRzd2e{YXTlJJRz[W6|cH;yeEBw\iCobIXvdoV{[2WwdDDndoFvfWyncx?= MmDZNlUzOzl3MEe=
KMS-6 NV\PXG9KTnWwY4Tpc44hSXO|YYm= MYGxxsDPxE4EoB?= MXSyOEBp MYLlfIhq[mm2czDoZYxnKHSqZTDz[YNz\XSrb36gc4Yh\2GuYX7pck1NUSCjczDkbYQhfGinIHPvcpRzd2x? M4CxV|I2OjJ7MUK2
MEC MoHBSpVv[3Srb36gRZN{[Xl? MmmxNUDPxE1? NX7Xb|k5OS53IHi= MnXXZ4F2e2W|IHGg[JJidWG2aXOg[IVkemWjc3WgbY4hfGinIIP1doZi[2ViVlXHSnIz NWDBOmI2OjV{Mki4NVU>
HEK293/hERG MkH3SpVv[3Srb36gRZN{[Xl? M4PoPVExyqEQvF2= NYWzUJVUOcLiaB?= MYny[ZN2dHS|IHnuJIEhfGmvZT3k[ZBmdmSnboSgdoVlfWO2aX;uJI1ifHW{ZTDoSXJIKHC{b4TlbY7DqA>? NHrocJAzPTJzOES2PS=>
RBE4 NGjWUHBCeG:ydH;zbZMhSXO|YYm= MmrHNuKh|ryP MlrON-KBmzJ2wrDo NIfuc2RqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nIHTldIVv\GWwdHz5 NVv4[ZJbOjVzMkiwNlU>
RBE4 MlvqSpVv[3Srb36gRZN{[Xl? MljSNuKh|ryP MVyz5qCUOjUEoHi= MnLQbY5kemWjc3XzJJRp\SC[QmCxJJBzd3SnaX6gcIV3\Wy|IHHmeIVzKDNiYX7kJFbDqGhib3[geJJm[XSvZX70 MXuyOVEzQDB{NR?=
RBE4 NIm5bWRHfW6ldHnvckBCe3OjeR?= NVXicnloOsLizszN MlzSN-KBmzJ2wrDo MXzpcoNz\WG|ZYOgZYN1cX[nIHPhd5Bie2VvMUKgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYNCpC=> MmPDNlUyOjhyMkW=
RBE4 M1\mNmZ2dmO2aX;uJGF{e2G7 NFnIWpUzyqEQvF2= NHqwV5A{6oDVMkVCpIg> NXW2V2FNcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gVm9UKHSrbXWt[IVx\W6mZX70cJk> M2jpNVI2OTJ6MEK1
RBE4 MnnwSpVv[3Srb36gRZN{[Xl? NETYVnozyqEQvF2= MUKz5qCUOjUEoHi= Ml\NbY5lfWOnczDhJIRmdGG7ZXSg[IVxdGW2aX;uJI9nKHSqZTDFVkBE[TJtwrDjc451\W62IHH0JFbDqGhib3[gbY5kfWKjdHnvckB{cWewaX\pZ4FvfGy7 MoCzNlUyOjhyMkW=
RBE4 MV7GeY5kfGmxbjDBd5NigQ>? M{[5UVLDqM7:TR?= MVKz5qCUOjUEoHi= NGnDeI1qdmS3Y3XzJIFvKG:4ZYLsc4FlKG:oIFPhNkvDqGmwIITo[UBucXSxY3jvcoRzcWFiaX6geIhmKG[rcoP0JFbDqGhib3[gbY5kfWKjdHnvckApeOLCiU|ihKkxNjByMTmgZpV1KEOjMjxCpIxmfmWuczDpckB1cGm|IH;y[4Fv\WyuZTDk[YNz\WG|ZXSgZYZ1\XJiMUNCpIghd2ZiaX7jeYJifGmxbh?= M{XK[|I2OTJ6MEK1
Huh-7  NFrkb5FHfW6ldHnvckBCe3OjeR?= NIi5XY4y|rypL33M Mn3TN-KBmzJ2wrDo M3zieYlv[3KnYYPld{B1cGVibHX2[Ywhd2ZiQWDFNUBqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NFXK[HUzPTB{NkG3OC=>
HepG2  MV3GeY5kfGmxbjDBd5NigQ>? M3qxflHPxGdxbVy= NGfnUJg{6oDVMkVCpIg> NYDRS5p{cW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDBVGUyKGmwIHGgeIlu\S2mZYDlcoRmdnRibXHucoVz NV\HRox[OjVyMk[xO|Q>
H838-LKB1 M164[mZ2dmO2aX;uJGF{e2G7 MoTKN|DDqG6pL33s NXO4fop{OTJxMUigbC=> NX:zVmZ5cW6lcnXhd4V{KHSqZTDwdo91\WmwIHzleoVteyCxZjDCbXDDqA>? Mn\aNlUxOTFyOEK=
H838-KDLKB1  MXjGeY5kfGmxbjDBd5NigQ>? NYDEXWRZOzEEoH7nM41t MUGxNk8yQCCq MoLUbY5kemWjc3XzJJRp\SCycn;0[YlvKGyndnXsd{Bw\iCEaWFCpC=> NWLLd4JJOjVyMUGwPFI>
H838-KDLKB1  MmKwSpVv[3Srb36gRZN{[Xl? NHKwSGk{OMLibnevcYw> MXqxNk8yQCCq NVK0[GVCcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gdIhwe3Cqb4L5cIF1\WRiZVnGNu6yKCiyaH;zdIhwNWWLRkNOtUk> MUiyOVAyOTB6Mh?=
3T3-L1 NVLMe2VPTnWwY4Tpc44hSXO|YYm= MX:1JO69\y:vbB?= NVSzTHNoOzBibXnu NIi3PW9ucW2rY4OgeIhmKGWoZnXjeJMhd2ZiaX7zeYxqdiCjbnSgZ4F2e2W|IILvZpV{fCCyaH;zdIhwenmuYYTpc44hd2ZiQXv0JEhU\XJiNEezLUBidmRicHjvd5Bpd3K7bHH0bY9vKG:oIFHTNVYxKCiWaIKgOlQzKGGwZDDT[ZIhPTh6KR?= NGPrO4YzPDh2M{iyOy=>
3T3-L1 NUL5S3d7TnWwY4Tpc44hSXO|YYm= NU\xXYQ4PSEQvHevcYw> NWXGSJlsOzBibXnu MkX2doVk[XCrdIXsZZRmeyCrboP1cIlvKGGldHnvckB4cXSqIILld5Bm[3RidH:gdoVofWyjdHnu[{BCc3RiYXP0bZZqfHliYX7kJGFUOTZyIIDoc5NxcG:{eXzheIlwdg>? NX[0V4k2OjR6NEO4Nlc>
3T3-L1 NWKyZ4psTnWwY4Tpc44hSXO|YYm= NUOxemdDPSEQvHevcYw> M{G5SlMxKG2rbh?= M1fSN4NifXOnczDy[ZZmenOrYnzlJJJm\Gm|dILpZpV1cW:wIH;mJGdNXVR2 MX6yOFg1Ozh{Nx?=
3T3-L1 MlrLSpVv[3Srb36gRZN{[Xl? NUmyRYRGPSEQvHevcYw> NUjC[3QzOcLiaB?= NIHTRmdk[XW|ZYOgdoVlcXO2cnnieZRqd25ib3[gS2xWXDRiYoX0JI5wfCCrbnPy[YF{\SCrbjDncJVkd3OnIIXweIFs\Q>? MlnnNlQ5PDN6Mke=
3T3-L1 NFPSZWpHfW6ldHnvckBCe3OjeR?= NEnxWYY2KM7:Zz;tcC=> NWLOXHlzOcLiaB?= MVzjZZV{\XNicHjvd5Bpd3K7bHH0bY9vKG:oIITo[UBHd3iRMTD0doFve2O{aYD0bY9vKG[jY4Tvdi=> MXGyOFg1Ozh{Nx?=
HeLa  NFPUeoxHfW6ldHnvckBCe3OjeR?= MlXtOUDPxGdxbXy= MkfsN{Bp NH7EfIRk[XW|ZYOgcpVkdGWjcjDlfINtfXOrb36gc4YhfGinIF\vfG8yKHS{YX7zZ5JqeHSrb36g[oFkfG:{IHHu[EBl\WO{ZXHz[ZMhfHKjboPjdolxfGmxbjDv[kBHd3iRMT3y[Yd2dGG2ZXSg[4Vv\XN? M1X5XlI1QDR|OEK3
HEK293 MnjkSpVv[3Srb36gRZN{[Xl? Mlf1OeKh|rypL33s NVHCPY97OTMEoHi= NFjOeWJi[m:uaYPo[ZMhS02DLXnu[JVk\WRiQ2LFUGQzKHOnY4LleIlwdg>? M2DXOFI1Pjh5NEOx
COS-1 NU\rOJBtTnWwY4Tpc44hSXO|YYm= NGjFemQ2KML3Zz;tcC=> MoezNlQhcMLi NWXOR3V4emW|dILpZ5R{KGyxY3HsbZpifGmxbjDv[kBPSiCrbjD0bIUheGW{aX71Z4xm[XJicnXnbY9vyqB? M4m5W|I1PjdzN{Wx
PRP NEjPSnVHfW6ldHnvckBCe3OjeR?= NFfzNJEyOCEQvF2= NGnpPVFi[nKxZ3H0[ZMhW0SILUJOtU1u\WSrYYTl[EBEYEOUNzDlfJRmem6jbHn6ZZRqd28EoB?= NGfTcGkzPDZ4OEe1NC=>
RAW264.7 MmTjRZBweHSxc3nzJGF{e2G7 NUPUc4hpPCEQvF2= MmLxOFghcA>? NH2zUFFifHSnboXheIV{KHSqZTDpcohq[mm2aX;uJI9nKG:6LVzEUE1qdmS3Y3XkJIFxd3C2b4Ppd{BidmRidHjlJIZi[2muaYTheIlwdiCxZjDjbI9t\XO2ZYLvcEBm\m[udYigZpkhSWNvaFWtNVhCNU6KMh?= NHfLdIwzPDZ|OUCzNi=>
MDMs NV;xd4hZSXCxcITvd4l{KEG|c3H5 NEK0W2syOOLCid88[{9udA>? NUCwRmFqOTJxMUWgbC=> M2K2RYlv\HWlZYOgZZBweHSxc3nz NV;ROodZOjR3NU[2PVU>
PMHs  MmXnSpVv[3Srb36gRZN{[Xl? NUDyUZk3OTEkgKOyNQKBkc7:Zz;tcC=> NYjFPZQ3OjUkgJno NYfrSnhPTE2VTx?= NUfUXop{cW6mdXPl[EBGWiC|dILld5M> NYnNW|BQOjR2MEeyOFI>
PMHs  NFzsTYVCeG:ydH;zbZMhSXO|YYm= NVmyPWJROTEkgKOyNQKBkc7:Zz;tcC=> NF[0WnIzPOLCiXi= M2TqSmROW09? NEHjeWJqdmO{ZXHz[ZMh[2WubDDk[YF1cA>? NXnI[ZZWOjR2MEeyOFI>
HEK293/tau MojPSpVv[3Srb36gRZN{[Xl? NID3TG42KM7:TR?= M1XrNlEwOi92IHi= NVj3NFRUcW6mdXPld{BId2ypaTDmdoFodWWwdHH0bY9vyqB? NVP3R3RZOjR|NkiwPFk>
HEK293/tau MYPGeY5kfGmxbjDBd5NigQ>? MVS1JO69VQ>? NIn2dZo{KGh? NHrwb5BqdmS3Y3XzJJRifSCqeYDldpBpd3OyaH;yfYxifGmxbh?= MoH4NlQ{PjhyOEm=
ADF NYqzS4ZwTnWwY4Tpc44hSXO|YYm= NVvjVndXOTBizszN NH;zSnEyPiCq MoqwbY5pcWKrdIOgeIhmKFqwQ3yyMYlv\HWlZXSgeJJidnOub3PheIlwdiCxZjDDVnQ> MYWyOFIzQDJ|Mh?=
U373  MYXGeY5kfGmxbjDBd5NigQ>? NEDnN5EyOCEQvF2= NF;vVWcyPiCq MWrpcohq[mm2czD0bIUhYm6FbEKtbY5lfWOnZDD0doFve2yxY3H0bY9vKG:oIFPSWC=> NWfQRmNPOjR{MkiyN|I>
RKO-HIPK2i NIrZcWlHfW6ldHnvckBCe3OjeR?= NXm4OG4xOTBizszN MXSxOkBp NH;2cYFqdmirYnn0d{B1cGViWn7DcFIucW6mdXPl[EB1emGwc3zvZ4F1cW:wIH;mJGNTXA>? M3v6WlI1OjJ6MkOy
ADF  NV3PO2d6TnWwY4Tpc44hSXO|YYm= NHHGXoEyOCEQvF5CpC=> M3nmWlYhcA>? M4XQUolueGGrcoOgeIhmKESFIHHjeIl3[XSrb36= NX21OJNPOjR{MkiyN|I>
Huh7 M4\Q[2Z2dmO2aX;uJGF{e2G7 MkDVOUDPxGdxbXy= MlO5OEBp NVX0U2tp[WKxbHnzbIV{KHSqZTDz[YNz\XSrb36gc4YhKGmwdILhZ4VtdHWuYYKgRZBwSg>? NW\NVXNKOjRzMECxOFA>
Huh7 M{nkeWZ2dmO2aX;uJGF{e2G7 NXrBTlM2PSEQvHevcYw> NIP3NXgyKGh? NEfTV2tk[XW|ZYOgZUB{cWewaX\pZ4FvfCCrbnPy[YF{\SCrbjDBdI9DNWO{ZYPj[Y51ew>? M1nCflI1OTByMUSw
Huh7 NIXI[o5HfW6ldHnvckBCe3OjeR?= M3u2bFXjiJNzMNMgcocwdWx? MUixNkBp NXX4[5JVcW6lcnXhd4V{KEGyb1KtZ5Jme2OnboTzJJdqfGixdYSgbY5pcWKrdHnu[{B{\WO{ZYTpc44> NXTkSXNnOjRzMECxOFA>
BAECs NHn0XpZHfW6ldHnvckBCe3OjeR?= MWi1JO69\y:vbB?= MWqwMVQhcA>? NXTLU|QzcW6mdXPld{B1cGVicnHwbYQh\GWyaH;zdIhwenmuYYTpc44hd2ZiZV7PV{BifCCVZYKxNVc6 Mnq3NlQxQDV{MkW=
Macrophages NGXtSYpHfW6ldHnvckBCe3OjeR?= M2HS[lcyKML3TR?= MnvIOkBp MUPpcohq[mm2czDseY5ie2mwIHnueIVzdmGuaYrheIlwdsLi M{LwTVI1ODN7N{Sw
Colo 205 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonSNE02KM7:Zz;tUC=> NUDxeHhQPDhiaB?= MUfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiC|dYPw[Y5{cW:wIHP1cJR2emW|IIfpeIgh[W5iZYP0bY1ifGWmIFnDOVAhd2ZifkG1JI5oN22O NYPrUJR2OjN7N{O5PVY>
Colo 205 NF;tVnlHfW6ldHnvckBCe3OjeR?= MXKwMlAyOi1yLkCyOUDPxGdxbVy= NUX3XYJIOTRiZB?= M4LnXpJm\HWlZYOgeIhmKGOub37v[4VvcWOrdImgc4YhS2:ubzCyNFUhS1OFcx?= NX7ub2RtOjN7N{O5PVY>
Colo 205 NWK3SVY1SXCxcITvd4l{KEG|c3H5 M1W0dlAvOSEQvHevcWw> M{nzVFAuOjRiaB?= NViwbYlDcW6mdXPld{BieG:ydH;zbZMhd2ZiQ3;sc{AzODViY3XscJMhcW5ic4XzdIVve2mxbjDjeYx1fXKncx?= M3vXclI{QTd|OUm2
Colo 205 NFSxV49HfW6ldHnvckBCe3OjeR?= MYCwMlAyPSEQvHevcWw> MnrzNlQhcA>? M2fKbolv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gSXIhe3S{ZYPzMZJmdGG2ZXSg[4Vv\XN? MX:yN|k4Ozl7Nh?=
Colo 205 MkX0SpVv[3Srb36gRZN{[Xl? M{fZ[VAvODF3IN88[{9uVA>? M2jaT|I1KGh? M1v5b4lvcGmkaYTzJJRp\SCjY4Tpeol1gSCxZjDNUXB{ NVPFZ3dLOjN7N{O5PVY>
IBRS2 NGXBVolHfW6ldHnvckBCe3OjeR?= M4XHPFUh|rypL33s M{DYTlAvPSCq M3PoUWROW09? MWjkbZNzfXC2czD0bIUhTVKJSVOgZY5lKEexbHfpxsA> MVWyN|k3OzV|NB?=
IBRS2 MljjSpVv[3Srb36gRZN{[Xl? MlKyOUDPxGdxbXy= MlTPNE42KGh? NF3OVGJFVVOR NEK2R2lmdmijbnPld{BHVUSYIHnu[oVkfGmxbh?= M{TuPVI{QTZ|NUO0
HeLa M3vkcWZ2dmO2aX;uJGF{e2G7 MkLSNkDPxE1? M3PhWVIhcMLi M4jvOIF1fGWwdXH0[ZMhfGinIGTOSk1qdmS3Y3XkJJNm[3KndHnvckBw\iCLTD2xOS=> NX7HeHF{OjN7NUC4PVI>
HFS  Ml7mSpVv[3Srb36gRZN{[Xl? NYLpTGJjOC1zIN88[{9udA>? NEfqWIkzPCCq M2D6N2dNXFBiZYjwdoV{e2mxbjDy[YFkcGW|IHGgdIxifGWjdTDheEBkd26lZX70doF1cW:wczDhd{Btd3diYYOgNE4xOSEEtXevcYw> NVi3UoZPOjN6OUS2N|M>
HFS  MUjGeY5kfGmxbjDBd5NigQ>? MkDTNE4xOSEEtXevcYw> MWOyOEBp M3PIPIlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBodHmlb4PwbIlv\2:uaYDp[EB{gW62aHHz[UBo\W6nczDheEA3KGh? M{nJb|I{QDl2NkOz
OVCAR-3 NGPYSGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPiUlNGOeLCk{G1xsDPxE4EoB?= M2DyVlI1yqCq MkXQbY5lfWOnczDhJIxwe3Nib3[gZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgcLi NXznRmxvOjN6Mk[5OlQ>
OVCAR-3 NYPLPXlmTnWwY4Tpc44hSXO|YYm= NH\MPYsy6oDVMUZCpO69VcLi NX3vZoFTOjUEoHi= MmnObY5lfWOnczDueYNt\WG{IHThcYFo\Q>? NHPzd4IzOzh{Nkm2OC=>
OVCAR-3 MlXrRZBweHSxc3nzJGF{e2G7 NI\3RWgyNTFywrFOwG0> NGi3dGk1KGh? NF;LXVRqdmS3Y3XzJJRp\SCjY4TpeoF1cW:wIH;mJIFxd3C2b4Ppd{1z\WyjdHXkJJBzd3SnaX7z NHPKeoEzOzh{Nkm2OC=>
OVCAR-3 MmjBRZBweHSxc3nzJGF{e2G7 MVSxNOKh|ryP M1nnNlI1yqCq MmHzbY5lfWOnczDhZ5RqfmG2aX;uJI9nKGOjc4Dhd4V{ NGi3VIQzOzh{Nkm2OC=>
OVCAR-3 MUnGeY5kfGmxbjDBd5NigQ>? NI\2UXEy6oDVMUFCpO69VQ>? M1riV|I1yqCq M2PGcolv\HWlZYOg[Il{enWydHnvckBw\iC2aHWgcYl1d2Oqb37kdolidCC2cnHud41mdWK{YX7lJJBwfGWwdHnhcC=> M4fqNlI{QDJ4OU[0
OVCAR-3 NX7KTpNlTnWwY4Tpc44hSXO|YYm= M2KwdVHjiJNzMNMg{txO NYrV[FdEOjUEoHi= NX[1O|BUcW6mdXPld{Bnd3KvYYTpc44hd2ZicnXhZ5RqfmVib4j5[4VvKHOyZXPp[ZM> NEjy[lczOzh{Nkm2OC=>
OVCAR-3 NHzDU|RHfW6ldHnvckBCe3OjeR?= M4jL[VHjiJNzMNMg{txO NEDHT3MzPMLiaB?= NUfDO41VcW6qaXLpeJMh[2WubDDh[Ihme2mxbjDhcoQhdWmpcnH0bY9v NFnLeoQzOzh{Nkm2OC=>
MKN45 MmPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33mNGlEPTB:MD6wNFEh|rypL33s M1G0U|I{Pzl|M{Sy
LOVO NELtZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3wbnpKSzVyPUCuNVIh|rypL33s M4DRZlI{Pzl|M{Sy
A549 Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L3VWlEPTB;MD6wOEDPxGdxbXy= MljKNlM4QTN|NEK=
MDA-MB-435 MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHUTWM2ODxyLkCwNUDPxGdxbXy= NXXyOIZQOjN5OUOzOFI>
HepG2 NG\iOnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LHdGlEPTB:MD6wNFEh|rypL33s MUiyN|c6OzN2Mh?=
HL-60 Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGew[3FKSzVyPECuNFAyKM7:Zz;tcC=> NITqTmczOzd7M{O0Ni=>

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:

[5]

+ Expand
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method:

    HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products0

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID